共 53 条
Design of novel proliposome formulation for antioxidant peptide, glutathione with enhanced oral bioavailability and stability
被引:35
作者:
Byeon, Jong Chan
[1
,2
]
Lee, Sang-Eun
[1
,2
]
Kim, Tae-Hyeon
[1
,2
]
Ahn, Jung Bin
[1
,2
]
Kim, Dong-Hyun
[1
,2
]
Choi, Jin-Seok
[1
,2
,3
]
Park, Jeong-Sook
[1
,2
]
机构:
[1] Chungnam Natl Univ, Coll Pharm, 99 Daehak Ro, Daejeon 34134, South Korea
[2] Chungnam Natl Univ, Inst Drug Res & Dev, Daejeon, South Korea
[3] Chodang Univ, Dept Med Management, Jeollanam Do, South Korea
基金:
新加坡国家研究基金会;
关键词:
Proliposome;
peptide drug;
glutathione;
oral drug delivery system;
IN-VITRO;
POTENTIAL CARRIERS;
DRUG-DELIVERY;
BILE-SALT;
LIPOSOMES;
CHITOSAN;
VIVO;
NANOPARTICLES;
ENCAPSULATION;
ABSORPTION;
D O I:
10.1080/10717544.2018.1551441
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
To develop proliposome formulations to improve the oral bioavailability of l-glutathione (GSH), GSH-loaded proliposomes were prepared using the granule method. Mannitol was selected as an effective excipient to achieve the desired particle size, entrapment efficiency (EE), and solubility for oral delivery of the final formulation. To evaluate the effect of surface charge of proliposomes on the oral bioavailability of GSH, negative (F1-F4) and positive proliposomes (F5-F9) were prepared. Particle size of F1 and F5 was 167.8 +/- 0.9 and 175.9 +/- 2.0 nm, and zeta potential of F1 and F5 was -8.1 +/- 0.7 and 21.1 +/- 2.0 mV, respectively. Encapsulation efficiency of F1 and F5 was 58.6% and 54.7%, respectively. Considering their particle size, zeta potential, and EE, the proliposomes F1 and F5 were adopted as the optimal formulations for further experiments. Solid state characterization of the proliposomes confirmed lipid coating on the surface of mannitol. The release of GSH from F1 and F5 formulations was prolonged until 24 h and pH independent. The total antioxidant capacity of GSH was concentration-dependent and maintained after formulation of GSH proliposomes. Circular dichroism spectroscopy confirmed that the molecular structure of GSH was maintained in the proliposome formulations. GSH proliposomes exhibited no significant changes in particle size and zeta potential for 4 weeks. An oral bioavailability study in rats revealed that F5 exhibited 1.05-, 1.08-, and 1.11-fold higher bioavailability than F1, commercial capsule formulation, and pure GSH, respectively. In conclusion, the prepared GSH proliposomes enhanced the poor bioavailability of GSH and prolonged its duration of action.
引用
收藏
页码:216 / 225
页数:10
相关论文